{"id":"hum0294","version":1,"url":"https://humandbs.dbcls.jp/research/hum0294/v1","datePublished":"2024-05-29","versions":[{"version":1,"datePublished":"2024-05-29"}],"title":{"ja":"腫瘍浸潤T細胞サブセットのシングルセル解析","en":"Single cell analysis of tumor-infiltrating T cells"},"summary":{"aims":{"ja":"｢切除不能局所進行食道扁平上皮癌を対象とした化学放射線療法後の逐次治療としてのアテゾリズマブ単独療法の安全性及び有効性を検討する多施設共同第Ⅱ相臨床相試験｣に付随するバイオマーカーの探索研究（通称：TENERGY-TR）に参加した食道がん患者の治療前の腫瘍と正常細胞のwhole exome sequencing（WES）解析と、治療前、放射線化学療法後、アテゾリズマブ投与後の3点の腫瘍生検検体のRNA-seq解析を実施し、治療効果予測バイオマーカー探索につなげること","en":"The objective is to analyze tumor and normal cell whole exome sequencing (WES) of esophageal cancer patients participating in the TENERGY-TR before treatment and RNA-seq specimens of tumor biopsy specimens at three points before treatment, after radiation chemotherapy, and after Atezolizumab administration, to search for biomarkers to predict treatment response."},"methods":{"ja":"各時点で取得した凍結腫瘍サンプルまたは血液サンプルを対象に、AllPrep DNA/RNA Mini kit（Qiagen）を用いてDNA/RNAを抽出し、WESならびにRNA-seq解析を実施した。","en":"DNA/RNA was extracted from frozen tumor or blood samples using an AllPrep DNA/RNA Mini kit (Qiagen) at each time point. Whole exome sequencing and RNA sequencing analyses were performed."},"targets":{"ja":"TENERGY-TRに参加した食道がん28症例。\n- WES：治療前の腫瘍組織（27検体）と正常組織（27検体）のペア、\n- RNA-seq：治療前（28検体）、放射線化学療法後（25検体）、アテゾリズマブ投与後（25検体）の3点の腫瘍生検検体","en":"- WES: tumor tissue (27 samples) and normal tissue (27 samples) from esophageal cancer patients\n- RNA-seq: tumor biopsy specimens at three-time points before treatment (28 samples), after radiation chemotherapy (25 samples) and after Atezolizumab administration (25 samples)"},"url":{"ja":[{"url":"https://doi.org/10.1186/s12885-020-06716-5","text":"https://doi.org/10.1186/s12885-020-06716-5"}],"en":[{"url":"https://doi.org/10.1186/s12885-020-06716-5","text":"https://doi.org/10.1186/s12885-020-06716-5"}]}},"listingSummary":{"methods":{"ja":"配列決定\n発現","en":"Sequencing, Expression profiling"},"targets":{"ja":"食道癌：28症例\n（日本人）","en":"esophageal cancer: 28 cases\n(Japanese)"},"typeOfData":{"ja":"NGS\n（Exome、RNA-seq）","en":"NGS\n(Exome, RNA-seq)"}},"releaseNote":{"ja":"食道がん28症例の腫瘍組織および非腫瘍組織から抽出したDNA/RNAを用いたWhole Exome Sequencing解析ならびにRNA-seq解析データをfastqファイルにて提供する。","en":"DNAs/RNAs extracted from tumor and non-tumor tissues of patients with esophageal cancer were used for the whole exome sequencing and RNA sequencing analyses. Fastq files are provided."},"dataProviders":[{"name":{"ja":"熊谷 尚悟","en":"Shogo Kumagai"},"organization":{"name":{"ja":"国立がん研究センター 先端医療開発センター 免疫トランスレーショナル分野","en":"Division of Cancer Immunology, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center"}}}],"researchProjects":[],"grants":[{"title":{"ja":"切除不能局所進行食道扁平癌を対象とした化学放射線療法後の逐次治療としての抗PD-1抗体薬療法の安全性・有効性・proof-of-concept (POC)を検討する多施設共同臨床第Ib/II相試験","en":"A phase II, multicenter study to investigate the safety, efficacy, and proof-of-concept (POC) of Anti PD-L1 antibody monotherapy following radical chemoradiotherapy in patients with inoperable locally advanced esophageal squamous cell cancer"},"agency":{"ja":"日本医療研究開発機構（AMED） 革新的がん医療実用化研究事業","en":"Practical Research for Innovative Cancer Control, Japan Agency for Medical Research and Development (AMED)"},"grantIds":["JP21ck0106420"]}],"relatedPublications":[{"title":"Atezolizumab monotherapy following dCRT indicated a promising cCR rate in patients with unresectable locally advanced esophageal squamous cell carcinoma (EPOC1802)","doi":"https://doi.org/10.1200/jco.2023.41.4_suppl.416","datasets":["JGAD000841"]}],"datasets":["JGAD000841"],"controlledAccessUsers":[{"principalInvestigator":{"ja":"浜田 道昭","en":"Michiaki Hamada"},"affiliation":{"ja":"浜田研究室, 理工学術院, 早稲田大学","en":"Hamada Laboratory, Faculty of Science and Engineering, Waseda University"},"country":{"ja":"日本","en":"Japan"},"researchTitle":{"ja":"RNA標的創薬データベースの構築","en":"Construction of RNA-targeted Drug Discovery Database"},"periodStart":"2023-01-05","periodEnd":"2027-10-31","datasets":["JGAD000841"]}]}